Navigation Links
Robust Biopharmaceutical Pipeline Offers New Hope for Patients
Date:1/17/2013

for an increasing proportion of the pipeline, and the number of potential new medicines for rare diseases averaged 140 per year in the last 10 years compared to 64 in the previous decade.

"Since 2005, the number of new medicines in development has grown by 40 percent," said John Lechleiter , Ph.D., chairman of PhRMA and chairman, president, and CEO of Eli Lilly and Company. "Our industry has been able to advance scientific discovery – along with the roster of potential new medicines – thanks, in part, to a policy environment that enables medical innovation to flourish. Public policies that value intellectual property, a strong regulatory system, and free market access for patients are critical to maintaining a robust innovation ecosystem and continuing to make progress fighting disease."

"On the eve of the presidential inauguration and in the midst of challenging fiscal pressures, we should renew our focus on the benefits of medical innovation for patient care, the economy and U.S. jobs," continued Castellani.  "The President has continually stressed the importance of innovation as a cornerstone to improving health and the U.S. economy, but to achieve these goals, we need patient-centric policies and continued collaboration among the public and private sectors."

The biopharmaceutical research sector currently supports nearly four million jobs in the U.S. and the overall impact of the sector on the domestic economy is $917 billion annually.  What's more, over the last decade, PhRMA member companies alone have invested $500 billion in research and development of new therapies for a wide range of diseases such as diabetes, heart disease and HIV/AIDS. 

The full report by the Analysis Group, as well as an

SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurostimulation Devices Market to 2018 - Technological Advances and Robust Pipeline with Multi-Indication Potential and Non-Invasive Therapies to Drive Growth
2. Frost & Sullivan Lauds U-Systems for Its Unique Technology and Strategic Excellence Paving the Way for Robust Growth
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
6. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
7. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
8. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
9. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
10. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
11. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... available in its catalogue: The Market ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle Eastern and ... medical devices. As part of its coverage, this ... concentrates on the EMEA medical device markets and ...
(Date:8/20/2014)... Aug. 20, 2014  Quantum Materials Corporation (OTCQB:QTMM) ... of patent families from Bayer Technology Services GmbH, the ... Bayer AG of Leverkusen, Germany ... broad intellectual property protection for advances Quantum ... dot (QD) manufacturing. In addition, the Bayer patents ...
(Date:8/19/2014)... , Aug. 19, 2014 Talyst, a market ... exhibiting at the 2014 NPPA Summer Conference in ... be showcasing its 340B software products and services.   ... splitting solutions, supplying over 400 customers with a variety ... 340B solutions including its latest solution, AutoSplit® Contract Pharmacy ...
Breaking Medicine Technology:The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4Talyst Exhibits at the NPPA Summer Conference 2
... at American Society of Clinical Oncology 2009 Annual Meeting ... , , SAN FRANCISCO, June 2 Medivation, ... presentation of new clinical results from a Phase 1-2 ... castration-resistant prostate cancer (CRPC) patients. The new findings, ...
... , Panel Discussant Focuses on Longer Duration of Remission ... Complete Remissions Achieved with Standard Chemotherapy , , ... MTA: CTIC) announced today that at the poster and ... Section at the 2009 American Society of Clinical Oncology ...
Cached Medicine Technology:Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 2Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 3Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 4Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 2Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 3Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 4Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 6
(Date:8/20/2014)... News) -- Pigs, hearts transplanted into baboons survived for ... as previously achieved, researchers report. The work is ... organs to shorten transplant waiting lists. In this ... baboons, abdomens. The genetic engineering and new methods of ... the hearts to survive for more than a year. ...
(Date:8/20/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... cancer cells grow may help doctors diagnose and treat the ... investigators have found that the deadliest skin cancers occur most ... a long history of sun exposure. These lesions also ... Rapid cell growth -- called "high mitotic rate" -- ...
(Date:8/20/2014)... persistent and deadliest infectious diseases in the world, killing ... who study tuberculosis have long debated its origins. New ... Africa to seals and sea lions that brought the ... people there before Europeans landed on the continent. , ... Source of New World Human Tuberculosis," was published in ...
(Date:8/20/2014)... New York, New York (PRWEB) August 20, 2014 ... associated with the use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ... Liebhard LLP notes that two U.S. Senators from New ... (FDA) to seek a recall of the devices. In ... Charles Schumer, both Democrats, also implored the agency to ...
(Date:8/20/2014)... contrast to evidence that the amygdala stimulates stress ... Research Center, Emory University have found that the ... during the early development of nonhuman primates. , ... Journal of Neuroscience . , The amygdala is ... important for responses to threatening situations and learning ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3
... Red Compounds Financial Problems, According ... July 14 HealthLeaders-InterStudy, a,leading provider of healthcare ... the hospitals in the Los Angeles market are ... doing relatively well financially,and those that are barely ...
... and Blue Shield companies to,promote workplace wellness programs ... Recognizing that chronic,illness accounts for 75 percent ... on" approach to improving employee health and wellness ... prevention,and management. At a press briefing this morning ...
... of Health,and Hospitals announced its intent to award HMS ... and cost avoidance services,to the state,s Medicaid program. This ... the highest score in a competitive procurement process,for the ... the state, HMS recovered more than,$36 million for the ...
... Zimmer Holdings, Inc.,(NYSE: ZMH ; SWX: ZMH) statement:, ... that Zimmer,s,NexGen(R) knee implant had been recalled. In fact, ... used for minimally invasive,surgeries (MIS) and not the implant ... to a single surgical instrument and that additional,instrumentation options ...
... Bring Better Quality of Care and Improved Business Performance ... ... PITTSBURGH, July 14 Vocollect Healthcare Systems, Inc.,and SouthMed, Inc., ... healthcare market, announce a,strategic partnership, whereby SouthMed will resell AccuNurse,voice-assisted care ...
... Optimism is good for heart health, at least among ... Medical Center researcher Robert Gramling, M.D., D.Sc., found that ... cardiovascular disease actually experienced a three times lower incidence ... data did not support the same conclusion among women. ...
Cached Medicine News:Health News:Fragmented Los Angeles Hospital Market Provides Health Systems with Little Leverage to Negotiate Higher Reimbursement 2Health News:Employers Take Active Role in Promoting Workplace Wellness 2Health News:Employers Take Active Role in Promoting Workplace Wellness 3Health News:Louisiana Department of Health and Hospitals Announces Intent to Award Cost Containment Services Contract to HMS 2Health News:Zimmer Holdings Issues Clarification Regarding NexGen Knee System 2Health News:Zimmer Holdings Issues Clarification Regarding NexGen Knee System 3Health News:SouthMed, Inc. and Vocollect Healthcare Systems Announce Reseller Agreement 2Health News:Positive thinking is prescription for the heart 2
An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Jerome Halo Traction Units provide optimum immobilization for unstable injuries of the spine. The Generation 80 superstructure is available with either 2-point (serrated disk), or 3-point (flexion/ex...
... Boston Scoliosis Brace™ for neuromuscular ... a lightweight, soft, and easy ... maximum comfort. The Soft ... of non-cracking orthopedic grade copolymer ...
An indirect immunofluorescence antibody test for the qualitative and semi-quantitative detection of endomysial antibodies (EMA) in human serum as an aid in the diagnosis of celiac disease and dermati...
Medicine Products: